Previous close | 9.14 |
Open | 9.15 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 9.14 - 9.14 |
52-week range | 5.30 - 9.15 |
Volume | |
Avg. volume | 5,199 |
Market cap | 3.048B |
Beta (5Y monthly) | 2.35 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024). Summary: Q1 2024 financial performance The Company reports unaudited total revenue of US$114.9M1 (AU$175.0M), an increase of 18% on the prior quarter (US$97.1M2 or AU$148.1M). Revenue was primarily generated from sales of Telix’s prostate cancer imaging product Illuc
Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”) pursuant to which Telix will acquire QSAM (the “Merger”). On
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation[1] for the Company's investigational glioma imaging product, TLX101-CDx (Pixclara™[2], 18F-floretyrosine or 18F-FET).